A Multicenter, Randomized, Double-Blind Study Comparing Investigational Drugs Amlitelimab and BI 1015550 to Placebo in Patients with Interstitial Lung Disease Secondary to Systemic Sclerosis
Led by Scleroderma Research Foundation, Inc. · Updated on 2026-08-18
400
Participants Needed
34
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of different investigational drugs compared to placebo in people with Interstitial Lung Disease caused by Systemic Sclerosis. The goal is to see how these treatments affect lung capacity over a one-year period. This phase 2b study is randomized, double-blind, and placebo-controlled, aiming to find better options for managing this lung condition associated with scleroderma.
Participants will receive one of two investigational drugs or a matching placebo. One drug, Amlitelimab, is given as an injection under the skin by the study staff. The other drug, BI 1015550 Nerandomilast, is taken orally as tablets twice daily. The treatment lasts for 52 weeks, during which lung function and other health measures will be closely monitored.
Throughout the study, participants will undergo tests including lung function tests measuring forced vital capacity FVC, imaging scans to assess lung fibrosis, and questionnaires about breathing difficulties. Researchers will track changes from the start of treatment through Week 52. Safety and efficacy data will be collected during this time, and participants health will be carefully observed until the study concludes.
CONDITIONS
Brief Title
Platform Clinical Study for Conquering Scleroderma
Research Team
G
Gabrielle Khedr
K
Kevin O'Shea
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Amlitelimab (investigational drug)
BI 1015550 (Nerandomilast) (investigational drug)
Current guideline-recommended therapy (mycophenolate mofetil or cyclophosphamide)
What it is
Amlitelimab is an investigational monoclonal antibody targeting OX40 ligand (OX40L), administered as a subcutaneous injection.
BI 1015550 (nerandomilast) is an investigational oral phosphodiesterase 4 inhibitor (PDE4i), given as film-coated tablets.
Current standard therapy for SSc-ILD typically includes immunosuppressants such as mycophenolate mofetil (MMF) or cyclophosphamide (CYC), used to stabilize lung function and reduce progression.
Role in trial
Assigned as a randomized investigational treatment arm.
Assigned as a separate randomized investigational drug arm within the platform trial.
Not a trial arm; represents best available standard therapy for similar patients outside the study.
Primary use
Investigated to slow progression of interstitial lung disease in systemic sclerosis.
Tested to slow or reduce lung function decline in patients with SSc-ILD.
Indicated to reduce progression and improve or preserve lung function in SSc-ILD.
How it is given or performed
Amlitelimab is given by subcutaneous injection by study staff in regular intervals during the trial.
BI 1015550 is self-administered orally as film-coated tablets taken daily (BID).
Mycophenolate mofetil is usually taken orally daily; cyclophosphamide may be given orally or as intermittent intravenous infusions.
Evidence status
Currently under phase 2 trial investigation; no published evidence on efficacy or safety for SSc-ILD.
Currently under phase 2 trial investigation; no published evidence on efficacy or safety for SSc-ILD.
Multiple studies and guidelines support immunosuppressants (MMF, CYC) as beneficial for slowing lung function decline in SSc-ILD; evidence base more mature than for new investigational arms.
Important limitations
Risks, benefits, and long-term effects in SSc-ILD are not yet established; results are pending and limited to clinical trial setting.
Efficacy and safety profile in SSc-ILD are unknown; no published results at this stage of investigation.
Immunosuppressive therapies are associated with risk of infections, cytopenias, and other adverse effects; long-term organ protection is variable and not all patients respond.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Male or female 18 years of age or older at the time of consent
Diagnosed with systemic sclerosis based on 2013 American College of Rheumatology/European League Against Rheumatism criteria
Onset of systemic sclerosis symptoms within 7 years before screening
Modified Rodnan skin score less than 40
Evidence of interstitial lung disease with fibrosis on HRCT within 3 months before randomization
Forced vital capacity (FVC) predicted to be 45% or more
Diffusing capacity of the lung for carbon monoxide (DLCO) predicted to be 30% or more, corrected for hemoglobin
You will not qualify if you...
Clinically significant lung abnormalities not consistent with interstitial lung disease on HRCT (such as scarring from tuberculosis, sarcoidosis, or lung mass)
Infected ulcers or active gangrene at screening
History of scleroderma renal crisis within 6 months before screening
Forced expiratory volume in 1 second/FVC ratio less than 0.65 at screening
Previous stem cell, bone marrow, chimeric antigen receptor T-cell, or solid organ transplantation
Rituximab treatment within 6 months before screening
Treatment with cell-depleting therapies other than rituximab
Treatment with certain immunosuppressive or biologic drugs within 3 months before screening
Use of any investigational medication or device within 30 days or 5 half-lives before screening
Abnormal laboratory tests including low kidney function, elevated liver enzymes, low blood cell counts, or abnormal blood clotting tests
Any disorder or condition that could interfere with study participation or safety
Life-threatening disease with life expectancy under 12 months
Active tuberculosis or high risk for tuberculosis
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 52 weeks
Participants receive one of the investigational drugs or matching placebo. Amlitelimab is given by subcutaneous injection, and BI 1015550 (Nerandomilast) is taken orally twice daily. Lung function and health are monitored during this period.
Regular visits throughout the treatment period
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Similar Trials
Two-part Study of PRO-203 Administered Subcutaneously in Healthy Adults and Participants With Systemic Sclerosis Evaluating Safety and Dose Effects
Phase 2a Study of AlloNK Cord Blood-derived NK Cell Therapy Combined With Rituximab
for Relapsing B-cell Rheumatologic Diseases Including RA, Sjgrens, Myopathies, and Systemic Sclerosis
Study of EVM18001 Injection for Treating Active Refractory Systemic Lupus Erythematosus, Myasthenia Gravis, and Scleroderma in Adults
Building a Biological Sample Collection to Study Systemic Autoimmune Diseases and Improve Diagnosis and Treatment
Study of Patients with Systemic Sclerosis and Collection of Biological Samples
Within the RESO Reference Centre for Rare Autoimmune Diseases
Safety and Early Effectiveness Study of HN2301 Injection in Adults with Autoimmune Diseases Including Lupus, Scleroderma, and Rheumatoid Arthritis
Evaluating the BETY Exercise Program Based on the Biopsychosocial Model in Children and Adults with Scleroderma
Registry Study for Pregnant Women with Autoimmune and Rheumatic Diseases
Tracking Pregnancy and Baby Health Outcomes
Study of How Scleroderma Affects Chewing and Swallowing in Children and Adults
Assessing Physical and Psychosocial Health in Patients with Scleroderma
Study on Physical Function and Well-Being in Children and Adults Diagnosed With Scleroderma
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease.